Jayme Looper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jayme Looper has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Andrew N. Bubak
Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
2 shared publications - Maria A. Nagel
Department of Neurology, University of Colorado Anschutz School of Medicine, Aurora, USA
2 shared publications - Amalia Bustillos
Department of Neurology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, USA
1 shared publication - Amalia Luthens
Department of Neurology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, USA
1 shared publication - Andrew Kurtzman
Department of Veterinary Clinical Medicine University of Illinois Urbana Illinois USA
1 shared publication - Arpita Das
Division of Microbiology, Tulane National Primate Research Center, Tulane University, Covington, LA 70433, USA
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 67 (6)
Risk Factors for Pathologic Fracture in Dogs With Confirmed or Suspected Appendicular Osteosarcoma Treated With Low‐ or Standard‐Dose‐Rate Palliative External Beam Radiation Therapy
Pathologic fracture is a complication of bone cancer with probable increased risk following radiation therapy (RT). Low‐dose‐rate (LDR) RT can spare late‐responding normal tissues by allowing intrafraction DNA repair, which could also impact tumor response. This retrospective cohort study evaluated efficacy and fracture rate in canine patients ( n = 184) with confirmed or suspected appendicular osteosarcoma that received 10 Gy × 2 palliative RT on consecutive days with LDR (cobalt‐60) or standard‐dose‐rate (SDR, linear accelerator). The overall fracture rate was 21.7%. Patients treated with SDR (600 cGy/min, n = 46) and LDR (range 21.9–83.29 cGy/min, n = 152) did not differ in pathologic fracture rates (22.4% vs. 17.4%, respectively, p = 0.54) or median survival times (231 vs. 248.5 days, respectively, p = 0.448). Pathologic fracture rates did not differ on the basis of weight (50 kg) or location (24% forelegs, 18% hindlegs, p = 0.44). However, no dog ( n = 7) weighing less than 20 kg developed a fracture. Radiographs prior to RT were subjectively assessed for bone integrity. Dogs with predominantly lytic lesions did not have a significantly higher pathologic fracture rate (21.2%–31.69% lytic/mixed vs. 10%–12.5% proliferative, p = 0.054), suggesting that pretreatment radiographic appearance does not reflect fracture risk. Additionally, the presence of a pretreatment cortical bone defect was not associated with eventual fracture ( p = 0.7). Adjunctive chemotherapy improved survival time significantly ( p = 0.01). On the basis of our data, it is reasonable to compare response rates and survival outcomes in published studies using cobalt irradiation with reports using linear accelerators.
- 28 September 2026
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 67 (6)
Open AccessRisk Factors for Pathologic Fracture in Dogs With Confirmed or Suspected Appendicular Osteosarcoma Treated With Low‐ or Standard‐Dose‐Rate Palliative External Beam Radiation Therapy
Pathologic fracture is a complication of bone cancer with probable increased risk following radiation therapy (RT). Low‐dose‐rate (LDR) RT can spare late‐responding normal tissues by allowing intrafraction DNA repair, which could also impact tumor response. This retrospective cohort study evaluated efficacy and fracture rate in canine patients ( n = 184) with confirmed or suspected appendicular osteosarcoma that received 10 Gy × 2 palliative RT on consecutive days with LDR (cobalt‐60) or standard‐dose‐rate (SDR, linear accelerator). The overall fracture rate was 21.7%. Patients treated with SDR (600 cGy/min, n = 46) and LDR (range 21.9–83.29 cGy/min, n = 152) did not differ in pathologic fracture rates (22.4% vs. 17.4%, respectively, p = 0.54) or median survival times (231 vs. 248.5 days, respectively, p = 0.448). Pathologic fracture rates did not differ on the basis of weight (50 kg) or location (24% forelegs, 18% hindlegs, p = 0.44). However, no dog ( n = 7) weighing less than 20 kg developed a fracture. Radiographs prior to RT were subjectively assessed for bone integrity. Dogs with predominantly lytic lesions did not have a significantly higher pathologic fracture rate (21.2%–31.69% lytic/mixed vs. 10%–12.5% proliferative, p = 0.054), suggesting that pretreatment radiographic appearance does not reflect fracture risk. Additionally, the presence of a pretreatment cortical bone defect was not associated with eventual fracture ( p = 0.7). Adjunctive chemotherapy improved survival time significantly ( p = 0.01). On the basis of our data, it is reasonable to compare response rates and survival outcomes in published studies using cobalt irradiation with reports using linear accelerators.
- Open Access
- 5 January 2026
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 24 (2) , 229-239
A Multi‐Institutional Retrospective Study of 21 Dogs Having Undergone Hypofractionated Radiotherapy for Adrenal Tumours (2017–2024)
Radiation therapy (RT) has emerged as a promising non‐surgical approach for treating canine adrenal tumours. This multi‐institutional, retrospective study describes clinical outcomes for 21 dogs having been prescribed a course of hypofractionated image‐guided intensity‐modulated RT (IMRT) entailing delivery of 25–35 Gy total in 5 fractions given over 5–15 days for an adrenal tumour. Diagnoses were based on imaging (abdominal ultrasound or computed tomography) and biochemical testing. All dogs had unilateral or bilateral irregular adrenal masses with evidence of vessel compression or invasion. Adrenal masses were incidentally identified in 11 dogs. The clinical diagnoses included pheochromocytoma ( n = 13, 61.9%), adrenocortical adenocarcinoma ( n = 2, 9.5%) and unspecified ( n = 6, 28.6%). Among the 16 dogs with available follow‐up imaging, the rates of partial response and stable disease were 37.5% (6/16) and 62.5% (10/16), respectively. Mild gastrointestinal side effects related to RT were reported in four dogs (19%). Early death that could have been attributable to tumour or complications of treatment occurred in two dogs (9.5%) at 21 and 52 days post‐RT; one presenting with acute vomiting, and the other presenting with vomiting, tremors, and shock before death. Of the 15 deceased dogs, 4 (26.7%) died due to tumour‐related causes and 11 died due to unknown ( n = 2) or unrelated ( n = 9) causes. The median overall survival time was 377 days, with a median follow‐up time of 458 days for censored patients ( n = 6). The one‐ and two‐year survival rates were 59.4% and 34.7%, respectively. These data build upon prior published reports, demonstrating that RT can be associated with prolonged survival in dogs with adrenal tumours. Hypofractionated IMRT appears to offer a potential survival benefit even in dogs with major vessel invasion or comorbidities. Future research should focus on identifying risk factors for early death and determining which patient populations are most likely to benefit from RT.
- 5 January 2026
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 24 (2) , 229-239
Open AccessA Multi‐Institutional Retrospective Study of 21 Dogs Having Undergone Hypofractionated Radiotherapy for Adrenal Tumours (2017–2024)
Radiation therapy (RT) has emerged as a promising non‐surgical approach for treating canine adrenal tumours. This multi‐institutional, retrospective study describes clinical outcomes for 21 dogs having been prescribed a course of hypofractionated image‐guided intensity‐modulated RT (IMRT) entailing delivery of 25–35 Gy total in 5 fractions given over 5–15 days for an adrenal tumour. Diagnoses were based on imaging (abdominal ultrasound or computed tomography) and biochemical testing. All dogs had unilateral or bilateral irregular adrenal masses with evidence of vessel compression or invasion. Adrenal masses were incidentally identified in 11 dogs. The clinical diagnoses included pheochromocytoma ( n = 13, 61.9%), adrenocortical adenocarcinoma ( n = 2, 9.5%) and unspecified ( n = 6, 28.6%). Among the 16 dogs with available follow‐up imaging, the rates of partial response and stable disease were 37.5% (6/16) and 62.5% (10/16), respectively. Mild gastrointestinal side effects related to RT were reported in four dogs (19%). Early death that could have been attributable to tumour or complications of treatment occurred in two dogs (9.5%) at 21 and 52 days post‐RT; one presenting with acute vomiting, and the other presenting with vomiting, tremors, and shock before death. Of the 15 deceased dogs, 4 (26.7%) died due to tumour‐related causes and 11 died due to unknown ( n = 2) or unrelated ( n = 9) causes. The median overall survival time was 377 days, with a median follow‐up time of 458 days for censored patients ( n = 6). The one‐ and two‐year survival rates were 59.4% and 34.7%, respectively. These data build upon prior published reports, demonstrating that RT can be associated with prolonged survival in dogs with adrenal tumours. Hypofractionated IMRT appears to offer a potential survival benefit even in dogs with major vessel invasion or comorbidities. Future research should focus on identifying risk factors for early death and determining which patient populations are most likely to benefit from RT.
- Open Access
Simian Varicella Virus Pathogenesis in Skin during Varicella and Zoster
Primary simian varicella virus (SVV) infection and reactivation in nonhuman primates is a valuable animal model in the study of varicella zoster virus disease [varicella (chickenpox) and herpes zoster (shingles)]. To understand SVV pathogenesis in skin, we inoculated 10 rhesus macaques with SVV, resulting in varicella rash. After the establishment of latency, eight of the monkeys were immunosuppressed using tacrolimus with or without irradiation and prednisone and two monkeys were not immunosuppressed. Zoster rash developed in all immunosuppressed monkeys and in one non-immunosuppressed monkey. Five monkeys had recurrent zoster. During varicella and zoster, SVV DNA in skin scrapings ranged from 50 to 107 copies/100 ng of total DNA and 2–127 copies/100 ng of total DNA, respectively. Detection of SVV DNA in blood during varicella was more frequent and abundant compared to that of zoster. During varicella and zoster, SVV antigens colocalized with neurons expressing β-III tubulin in epidermis, hair follicles, and sweat glands, suggesting axonal transport of the virus. Together, we have demonstrated that both SVV DNA and antigens can be detected in skin lesions during varicella and zoster, providing the basis for further studies on SVV skin pathogenesis, including immune responses and mechanisms of peripheral spread.
Open AccessSimian Varicella Virus Pathogenesis in Skin during Varicella and Zoster
Primary simian varicella virus (SVV) infection and reactivation in nonhuman primates is a valuable animal model in the study of varicella zoster virus disease [varicella (chickenpox) and herpes zoster (shingles)]. To understand SVV pathogenesis in skin, we inoculated 10 rhesus macaques with SVV, resulting in varicella rash. After the establishment of latency, eight of the monkeys were immunosuppressed using tacrolimus with or without irradiation and prednisone and two monkeys were not immunosuppressed. Zoster rash developed in all immunosuppressed monkeys and in one non-immunosuppressed monkey. Five monkeys had recurrent zoster. During varicella and zoster, SVV DNA in skin scrapings ranged from 50 to 107 copies/100 ng of total DNA and 2–127 copies/100 ng of total DNA, respectively. Detection of SVV DNA in blood during varicella was more frequent and abundant compared to that of zoster. During varicella and zoster, SVV antigens colocalized with neurons expressing β-III tubulin in epidermis, hair follicles, and sweat glands, suggesting axonal transport of the virus. Together, we have demonstrated that both SVV DNA and antigens can be detected in skin lesions during varicella and zoster, providing the basis for further studies on SVV skin pathogenesis, including immune responses and mechanisms of peripheral spread.
- Open Access
- 22 September 2020
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 26 (6) , 945-951
Elevated serum substance P during simian varicella virus infection in rhesus macaques: implications for chronic inflammation and adverse cerebrovascular events
Varicella and zoster, produced by varicella-zoster virus (VZV), are associated with an increased risk of stroke that may be due to persistent inflammation and hypercoagulability. Because substance P is associated with inflammation, hypercoagulability, and atherosclerotic plaque rupture that may contribute to increased stroke risk after VZV infection, we measured serum substance P in simian varicella virus–infected rhesus macaques. We found significantly increased and persistent serum substance P concentrations during varicella and zoster compared with pre-inoculation, supporting the hypothesis that VZV-induced increases in serum substance P may contribute to increased stroke risk associated with VZV infection.
- 22 September 2020
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 26 (6) , 945-951
Open AccessElevated serum substance P during simian varicella virus infection in rhesus macaques: implications for chronic inflammation and adverse cerebrovascular events
Varicella and zoster, produced by varicella-zoster virus (VZV), are associated with an increased risk of stroke that may be due to persistent inflammation and hypercoagulability. Because substance P is associated with inflammation, hypercoagulability, and atherosclerotic plaque rupture that may contribute to increased stroke risk after VZV infection, we measured serum substance P in simian varicella virus–infected rhesus macaques. We found significantly increased and persistent serum substance P concentrations during varicella and zoster compared with pre-inoculation, supporting the hypothesis that VZV-induced increases in serum substance P may contribute to increased stroke risk associated with VZV infection.
- 1 March 2020
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 256 (5) , 545-547
What Is Your Diagnosis?
- 1 March 2020
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 256 (5) , 545-547
What Is Your Diagnosis?